ArticleKorean circulation journal2025
miR-140-5p Ameliorates Atrial Fibrillation in Cardiomyocytes by Targeting the Water Channel Protein Aquaporin 4.
Article in Korean circulation journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer.International journal of molecular sciences · 2026Review
- miR-140-5p and Water Channel Aquaporin 4: Opening a New Channel for Treating Atrial Fibrillation.Korean circulation journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectivesMicroRNAs (miRNAs) are small, non-coding RNAs that control gene expression patterns by inducing the degradation of messenger RNAs (mRNAs). Furthermore, miRNAs are known to play an important role in the pathogenesis of atrial fibrillation (AF). AF is typically diagnosed using an electrocardiogram. However, this study investigated whether specific miRNAs could be involved in alleviating AF by regulating aquaporin 4 (AQP4).
methodsHL-1 cells were transfected with either miRNA negative control (NC) or miR-140-5p, followed by incubation with or without tachypacing (TP) condition. We investigated the protein expression of calcium-handling and inflammation-related proteins in control, control + miR-NC, control + miR-140-5p, TP, and TP + miR-140-5p groups by Western blotting. Also, the relative mRNA expression of AQP4 was determined through real-time polymerase chain reaction.
resultsCompared to the control, miR-140-3p was increased in the TP-induced AF group. Additionally, AQP4 protein expression and mRNA level were increased in the AF group along with inflammation-related proteins toll-like receptor 4, nucleotide-binding domain-like receptor protein 3, ERK, AKT, and interleukin-1β. The increase in such proteins was mitigated through miR-140-5p treatment. In accordance with these results, calcium-handling protein markers CaMKII, phospholamban, and ryanodine receptor 2 gene were also increased in the AF group and alleviated with miR-140-5p treatment.
conclusionsmiR-140-5p is engaged in suppressing the expression of AQP4 in TP-induced AF HL-1 cells. In doing so, miR-140-5p reduced the risk of AF by suppressing inflammation and phosphorylation of Ca-handling proteins.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.